semaglutide cagrilintide Subcutaneous Cagrilintide, Shows Significant Weight Loss in Type 2 Diabetes Trial Semaglutide, a glucagon-like peptide-1 (GLP-1)
Description
Reporting issues to the FDA FDA encourages health care professionals, patients, and compounders to report adverse events or quality problems with these or any medications to FDAs MedWatch Adverse Event Reporting program: Complete and submit the report online
SOURCE: JAMA Ophthalmology , Feb
GLP-1 Receptor Agonists at CROI 2026: Revolution, Hype or the Beginning of a New Era
It is important to understand how this situation came to be and what considerations to think through going forward
If you've just started semaglutide injections, you're likely wondering when you'll feel the medication working
